← Eichor
Condition: Vulvovaginal Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Vulvovaginal Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Phase N/A · 1 location(s) · Scynexis, Inc. · NCT05908682Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
NA · 10 location(s) · Coologics, Inc · NCT06983041Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence
Phase 2 · 1 location(s) · Sano Chemicals Inc · NCT07521137Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs
NA · 1 location(s) · Mucosa Innovations, S.L. · NCT06962345The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study
NA · 2 location(s) · Guy's and St Thomas' NHS Foundation Trust · NCT05434104Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Can
Phase 2/Phase 3 · 7 location(s) · AVVA Pharmaceuticals Ltd. · NCT06835361Comparative Performance of a Vaginal Yeast Test
Phase N/A · 3 location(s) · Uniformed Services University of the Health Sciences · NCT05079711Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
EARLY_Phase 1 · 1 location(s) · Queen's Medical Center · NCT05753813Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
Phase N/A · 1 location(s) · Jessa Hospital · NCT07563621Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis
NA · 1 location(s) · Bioithas SL · NCT07603895Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections
NA · 1 location(s) · Karo Pharma AB · NCT07234786Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
Phase N/A · 1 location(s) · Case Comprehensive Cancer Center · NCT06649201Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
NA · 6 location(s) · The Archer-Daniels-Midland Company · NCT06480604Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
Phase 3 · 27 location(s) · pH-D Feminine Health LLC · NCT07109869The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
Phase 3 · 2 location(s) · Maastricht University Medical Center · NCT05367089A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients
Phase 2 · 2 location(s) · Cisen Pharmaceutical CO., LTD. · NCT06771063Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Phase 2 · 1 location(s) · Azure Biotech Inc. · NCT06197568Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
NA · 1 location(s) · Centre Hospitalier Universitaire Saint Pierre · NCT06828640Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05974449Randomized Study Evaluating the Treatment of Vulvovaginal Gaping by Plication of the Puborectalis Muscles Versus Perineo
NA · 1 location(s) · GCS Ramsay Santé pour l'Enseignement et la Recherche · NCT07245823Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
NA · 1 location(s) · Centre Oscar Lambret · NCT06900374
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.